| - Positioned to Capitalize on Growth Potential of Diabetes Treatment Industry - NEW YORK, March 23, 2012 /PRNewswire/ -- Islet Sciences, Inc. (OTC.BB: ISLT), a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc. ("DTI"), a biopharmaceutical company developing new, proprietary drugs for unmet medical need...continued ISLT |
Friday, March 23, 2012
Islet Sciences Announces Closing of DiaKine Therapeutics Acquisition
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment